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Abstract
Background: Congestive heart failure (CHF) has a substantial impact on care utilisation and quality of
life. It is crucial for patients to cope with CHF adequately, if they are to live an acceptable life. Self-
management may play an important role in this regard. Previous studies have shown the effectiveness of
the 'Chronic Disease Self-Management Program' (CDSMP), a group-based cognitive behavioural
programme for patients with various chronic conditions. However, the programme's effectiveness has not
yet been studied specifically among CHF patients. This paper presents the design of a randomised
controlled trial to evaluate the effects of the CDSMP on psychosocial attributes, health behaviour, quality
of life, and health care utilisation of CHF patients.
Methods/Design: The programme is being evaluated in a two-group randomised controlled trial. Patients
were eligible if they had been diagnosed with CHF and experienced slight to marked limitation of physical
activity. They were selected from the Heart Failure and/or Cardiology Outpatient Clinics of six hospitals.
Eligible patients underwent a baseline assessment and were subsequently allocated to the intervention or
control group. Patients allocated to the intervention group were invited to attend the self-management
programme consisting of six weekly sessions, led by a CHF nurse specialist and a CHF patient. Those
allocated to the control group received care as usual. Follow-up measurements are being carried out
immediately after the intervention period, and six and twelve months after the start of the intervention.
An effect evaluation and a process evaluation are being conducted. The primary outcomes of the effect
evaluation are self-efficacy expectancies, perceived control, and cognitive symptom management. The
secondary outcome measures are smoking and drinking behaviour, Body Mass Index (BMI), physical
activity level, self-care behaviour, health-related quality of life, perceived autonomy, symptoms of anxiety
and depression, and health care utilisation. The programme's feasibility is assessed by measuring
compliance with the protocol, patients' attendance and adherence, and the opinions about the programme.
Discussion: A total number of 318 patients were included in the trial. At present, follow-up data are being
collected. The results of the trial become clear after completion of the data collection in January 2007.
Trial Registration: Trialregister (http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=467)
ISRCTN88363287.
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Background
Effective management of congestive heart failure (CHF) is
one of the major challenges in health care today. The
number of CHF patients is substantial: CHF affects up to
20% of the rapidly increasing population of persons aged
65 years and over. Of every three individuals aged 55 years
and over, one will develop CHF during their lifetime, with
only 35% surviving 5 years following diagnosis [1]. In the
aging population of the Western world, this implies a fur-
ther expansion of the CHF epidemic in the near future
[2,3]. CHF has a substantial impact on care utilisation,
daily functioning, and quality of life [4,5].
There is increasing evidence that self-management pro-
grammes for CHF patients have positive effects on self-
care behaviour and quality of life [6-9]. Managing CHF is
a complex task, and comparable to diabetes in that it
touches nearly every important aspect of daily life [10]. It
is therefore crucial for patients to cope with CHF ade-
quately, if they are to live an acceptable life. Exercise intol-
erance, often experienced by CHF patients, may lead to
activity restriction and progressive functional deteriora-
tion. This downward spiral may be interrupted by physi-
cal activity, which may improve functional capacity and
quality of life [11]. In addition, diet and lifestyle changes,
such as limiting salt intake and balancing rest and activity,
are important to prevent complications and hospitalisa-
tion, and to slow the disease progression [12,13]. Self-
management skills such as fatigue management, breath-
ing techniques, and relaxation can play an important role
in everyday CHF management [14].
To teach patients how to adequately self-manage the con-
sequences of their chronic disease for daily life, Lorig and
colleagues developed the "Chronic Disease Self-Manage-
ment Program" (CDSMP) at Stanford University in Cali-
fornia (USA) [14-18]. The CDSMP is a structured group-
based self-management programme for people with
chronic conditions, addressing general management
problems for various chronic conditions. The CDSMP is
based on the self-efficacy theory developed by Bandura
[19] and incorporates skills mastery, reinterpretation of
symptoms, modelling, and social persuasion to enhance
self-efficacy expectancies [16,18]. Self-efficacy expectan-
cies refer to the belief that one can successfully perform
intended behaviours [19], and are powerful determinants
of behavioural change [20]. There are indications that low
levels of self-efficacy expectancies predict functional
decline in CHF patients [21]. Improving self-efficacy
expectancies may therefore change health behaviour,
improve health-related quality of life, and reduce care uti-
lisation by CHF patients.
Previous studies have found favourable effects of the
CDSMP (e.g. on self-efficacy expectancies and hospitalisa-
tion) in arthritis patients [22] and in groups of patients
with various chronic conditions attending the same class
[17,23], even after one and two years [15,16]. However,
the effects of the programme have not yet been studied
specifically among CHF patients. Our basic assumption is
that increasing levels of self-efficacy expectancies will help
CHF patients to interrupt the downward spiral of func-
tional disability and demoralisation after their cardiac
event. Therefore, we decided to evaluate the effects of the
CDSMP on psychosocial attributes (e.g. self-efficacy
expectancies), health behaviour, quality of life, and health
care utilisation of CHF patients. The current paper
presents the design of a multi-centre randomised control-
led trial evaluating the CDSMP among CHF outpatients in
the south of the Netherlands. The study involves an effect
evaluation and an evaluation of the intervention process.
The process analysis is expected to yield information on
factors increasing or hampering the effectiveness and
implementation of the programme in outpatient care for
CHF patients, which may be crucial later on if the group
programme turns out to be effective.
Aims
The main objectives of the current study are: (1) to assess
the effects of the cognitive behavioural CDSMP interven-
tion on psychosocial attributes, health behaviour, quality
of life, and health care utilisation of CHF patients, and (2)
to assess the feasibility of the CDSMP intervention accord-
ing to patients and leaders of the programme.
Methods/Design
Design
This evaluation study is designed as a two-group ran-
domised controlled trial in which patients are randomly
allocated to the intervention or control group (the latter
receiving usual care). Data are collected at baseline before
the start of the intervention, immediately after the pro-
gramme (six weeks after the start), and six and twelve
months after the start of the programme (see figure 1).
Data are gathered by means of self-administered question-
naires and telephone interviews. Various measures are
taken to ensure blinding in the data collection process.
Questionnaires are collected anonymously and sorted by
number. The telephone interviews are conducted inde-
pendently by trained interviewers, who are unaware to
which group patients have been allocated.
For practical reasons, the study consists of eleven consec-
utive cycles, with one or more CDSMP classes in each
cycle. In each cycle, patients are included and randomly
allocated to the intervention group or control group. The
first cycle started in July 2004 and the final one in Septem-
ber 2005. A total of 21 CDSMP classes (with a parallel
control group) were conducted in the period October
2004 – January 2006, in six hospitals. At least two CDSMPBMC Health Services Research 2006, 6:91 http://www.biomedcentral.com/1472-6963/6/91
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classes were conducted in each participating hospital
(range 2–6). The Medical Ethics Committee of Maastricht
University/University Hospital Maastricht granted
approval to conduct this trial. Furthermore, local feasibil-
ity of the study design was assessed by each of the local
Medical Ethics Committees in the other five participating
hospitals.
Participants
Patients were selected by cardiologists or CHF nurse spe-
cialists of the Heart Failure and/or Cardiology Outpatient
Clinics in the six participating hospitals. Patients were eli-
gible for the study if they met the following four criteria:
(1) having been diagnosed with CHF based on a systolic
dysfunction (left ventricular ejection fraction (LVEF) <
40% with New York Heart Association (NYHA) Class II-III
symptoms; slight to marked limitation of physical activ-
ity) or a diastolic dysfunction (LVEF ≥ 40% with NYHA
Class II-III symptoms plus an additional hospital admis-
sion based on decompensatio cordis after CHF diagnosis);
(2) having been a CHF patient for at least six months at
the start of the intervention period, (3) being able to
understand, write, and speak Dutch, and (4) being willing
to give informed consent to participate in the study.
Patients were excluded if they were participating in other
scientific research. All eligible patients received written
information about the programme and the study. Patients
who signed the informed consent form were invited to
participate in the baseline measurement.
Randomisation
In each cycle, patients were randomised after completion
of the baseline measurement if a sufficiently large group
of eligible patients per hospital could be formed. We
decided that at least eight patients per group had to be
allocated to the intervention group, because CDSMP
classes normally consist of at least eight participants, for
reasons of group dynamics [16]. Eligible patients there-
fore had a slightly higher chance to be allocated to the
intervention group (59%) than to the control group
(41%) during the total recruitment period. The maximum
number of patients allocated to each CDSMP class was set
at 14. The randomisation procedure was performed by an
independent researcher by random computerised alloca-
tion using SPSS 12.0 for Windows.
Intervention
The CDSMP consists of six weekly sessions (two and a half
hours per session) and emphasises patients' central role
and responsibility in managing their illness [16]. The pro-
gramme aims to teach patients three types of self-manage-
ment techniques: dealing with the medical management
of the disease (medical management); maintaining,
changing, and creating new meaningful behaviours or life
roles (role management), and dealing with the emotional
Study design Figure 1
Study design.
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consequences of having a chronic condition (emotional
management) [18]. These self-management techniques
are taught by means of skills mastery through weekly
action planning and feedback on progress, modelling of
self-management behaviours and problem-solving strate-
gies, reinterpretation of physiological symptoms, and
social persuasion through group support and guidance for
individual self-management efforts [16,18]. Table 1
shows the CDSMP activities per session. While developing
the CDSMP, Lorig and colleagues published the book Liv-
ing a healthy life with chronic conditions [14], as a reference
source for the material covered in the sessions. The
patients received this book at the first session of the pro-
gramme. Before the start of the study, the original pro-
gramme had been translated into Dutch, including Living
a healthy life with chronic conditions [14]. Some minor
adjustments were made in this translated version of the
reference book, based on differences between the Ameri-
can and Dutch settings (e.g. with regard to advance direc-
tives).
In the original version of the programme, CDSMP classes
are led by two trained lay leaders. For the present study,
however, we opted for a combination of a 'professional
leader' (a CHF nurse specialist) and a 'peer leader' (CHF
patient), acting as a role model for the other CHF patients
in the class. The reason was that we expect a programme
which is led by at least one professional leader to be easier
to implement in regular health care than a programme led
by two lay leaders only. Furthermore, CHF is a serious dis-
ease with unexpected exacerbations and intercurrent
health problems. This means that peer leaders may only
be able to conduct the programme for a limited period,
which could form a threat to the continuity of the pro-
gramme.
In four of the six hospitals, CHF nurse specialists and CHF
patients were trained as leaders. These leaders also con-
ducted CDSMP classes in the two other participating hos-
pitals. A total of twelve professionals and eleven CHF
patients received four days of training with the CDSMP
protocol in the period April 2004 – November 2005. Four
of the twelve professional leaders and two of the eleven
peer leaders did not implement the programme in the
intervention period, due to work, health, or private issues.
Each of the groups in which the leaders were trained (n =
4 to 6) included both professional leaders and peer lead-
ers, who practised together, to provide an optimal training
situation. The leader training was provided by one of the
researchers (author ES) and a CHF nurse specialist of the
University Hospital Maastricht in the Netherlands. Both
had been instructed as master trainers at Stanford Univer-
sity by Lorig and colleagues in March 2004. The nurse
master trainer also conducted several classes in the inter-
vention period.
Measurements in the effect evaluation
Primary outcome variables
The primary outcomes of the effect evaluation are psycho-
social attributes, conceptualised as self-efficacy expectan-
cies, perceived control, and cognitive symptom
management. The primary outcomes are assumed to be
directly influenced by the self-management programme.
Table 1: Contents of the CDSMP
Session1
Activity 1 Introduction – Identifying common problems
Activity 2 Workshop overview and responsibilities
Activity 3 Differences between acute and chronic conditions
Activity 4 Introduction to cognitive symptom management
Activity 5 Introduction to action plans
Activity 6 Closing
Session 2
Activity 1 Feedback/problem-solving session
Activity 2 Dealing with emotions (anger, fear, frustration)
Activity 3 Introduction to exercise
Activity 4 Making an action plan
Activity 5 Closing
Session 3
Activity 1 Feedback/problem-solving session
Activity 2 Better breathing
Activity 3 Muscle relaxation
Activity 4 Fatigue management
Activity 5 Endurance exercise
Activity 6 Making an action plan
Activity 7 Closing
Session 4 
Activity 1 Feedback/problem-solving/making an action plan
Activity 2 Healthy eating
Activity 3 Distraction
Activity 4 Advance directives for health care
Activity 5 Communication skills
Activity 6 Problem-solving
Activity 7 Closing
Session 5
Activity 1 Feedback/problem-solving/making an action plan
Activity 2 Medication usage
Activity 3 Making informed treatment decisions
Activity 4 Depression management
Activity 5 Self-talk
Activity 6 Guided imagery
Activity 7 Closing
Session 6
Activity 1 Feedback/problem-solving
Activity 2 Informing the health care team
Activity 3 Working with your health care professional
Activity 4 Looking back and planning for the future
Activity 5 ClosingBMC Health Services Research 2006, 6:91 http://www.biomedcentral.com/1472-6963/6/91
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Self-efficacy expectancies were assessed by two scales; one
is a generic scale, allowing us to compare our results with
other studies, whereas the other is a specific scale for car-
diac patients, used to improve the sensitivity to change in
our study population. General self-efficacy expectancies
were measured by the 'General Self-Efficacy Scale' (GSES)
[20], which determines the extent to which people believe
that they can successfully perform a particular behaviour.
Cardiac self-efficacy expectancies were measured using the
'Cardiac Self-Efficacy Questionnaire' [24], which has also
been used in other Dutch research among CHF patients
[25,26].
Perceived control was assessed by means of the mastery
scale developed by Pearlin and Schooler [27]. This scale
measures "the extent to which one regards one's life
chances as being under one's own control, in contrast to
being fatalistically ruled" [27]. The psychometric proper-
ties of the Dutch versions of the GSES and the perceived
control scale had proved satisfactory in previous studies
[21,28,29].
Cognitive symptom management was assessed by the
'Coping with symptoms scale' developed by Lorig and col-
leagues [30], which measures how often respondents use
cognitive symptom management techniques when they
feel depressed or experience pain or other unpleasant
symptoms. The original 6-item scale was slightly modified
into a 5-item scale by omitting the first two items and add-
ing one extra item about the use of breathing techniques
as a way to deal with unpleasant symptoms (Elzen et al.,
evaluation of the CDSMP among chronically ill elderly
people in the Netherlands, submitted). Table 2 provides
an overview of the outcome variables of the effect evalua-
tion.
Secondary outcome variables
The outcome measures considered to be indirectly influ-
enced by the programme (secondary outcomes) are health
behaviour, quality of life, and health care utilisation (see
table 2).
Health behaviour was operationalised into three measure-
ments: (1) smoking and drinking behaviour and Body
Mass Index (BMI) (kg/m2), (2) physical activity level, and
(3) self-care behaviour. Smoking and drinking behaviour
were assessed by asking the patients whether they smoked
or drank and in what amounts (i.e. mean number of ciga-
rettes/cigars/pipes smoked per day and mean number of
alcoholic drinks per week, respectively). Physical activity
level was measured by a modified version of the 'Physical
activities scale' developed by Lorig and colleagues [30].
This scale comprises questions about the frequency of
walking for exercise, swimming, and bicycling in the pre-
ceding month. In addition, respondents were given an
opportunity to name alternative exercises in an open-
ended question, such as gardening, housekeeping, etc.
Finally, CHF-specific self-care behaviour was measured
with the 'European Heart Failure Self-Care Behaviour
Scale' (EHFScBS), a scale developed in the Netherlands,
with good psychometric properties [31].
Quality of life was conceptualised as health-related qual-
ity of life, perceived autonomy, and symptoms of anxiety
and depression. Health-related quality of life was meas-
ured using both generic and disease-specific instruments;
the 'RAND 36-item Health Survey' (RAND-36) [32] and
the 'Kansas City Cardiomyopathy Questionnaire' (KCCQ)
[33]. Perceived autonomy was assessed by one item using
a visual analogue scale to measure to what extent the
patients were able to arrange their lives the way they
would like to (I do not feel I can do so at all – I strongly
feel I can do so). Symptoms of anxiety and depression
were measured by the 'Hospital Anxiety and Depression
Scale' (HADS) [34,35], which is considered to be unbi-
ased by coexisting general medical conditions [36]. The
psychometric properties of the Dutch versions of the
RAND-36 and the HADS have proved to be satisfactory in
previous studies [36,37].
Finally, health care utilisation was measured by patients'
self-reports on the number of contacts with a general prac-
titioner, cardiologist, other medical specialist or CHF
nurse specialist, the number of hospitalisation days, the
reason for hospitalisation, and the number of visits to
accident and emergency departments.
Covariates
Some additional variables were assessed to characterise
the study population and interpret the outcomes of the
trial (see table 2). Socio-demographics (gender, age, mar-
ital status, living arrangements, education level, and job
situation) were assessed at baseline. In addition, two
health-related variables were assessed at baseline: co-mor-
bidity using a 19-item checklist of medical conditions
[21,38] and cognitive status using the Dutch version of
the Telephone Interview for Cognitive Status (TICS)
[39,40].
Measurements in the process evaluation
To determine the feasibility of the programme, four proc-
ess outcomes were assessed by means of structured evalu-
ation forms: (1) the extent to which the programme was
performed according to protocol and the time spent on
the sessions, (2) patients' attendance, (3) overall patient
adherence and specific adherence with regard to home-
work assignments, and (4) the opinions of the patients
and leaders about the programme. Table 3 presents the
outcome variables of the process evaluation.BMC Health Services Research 2006, 6:91 http://www.biomedcentral.com/1472-6963/6/91
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With regard to compliance with the protocol, the leaders
recorded after each session whether they had exceeded
specified time limits per activity, skipped, shortened or
added parts to activities, or used different training tech-
niques than specified in the protocol. In addition, they
recorded preparation time, travel time, time spent on the
session, and activities resulting from the session (e.g.
answering patients' questions afterwards)
The leaders reported on patient attendance and adherence
at group level. Absent patients were phoned by the profes-
sional leader to ask for the reason of their absence. Overall
adherence (i.e. patients' efforts during the programme ses-
sions) was also assessed at group level, using a 5-point
scale (very good – very poor). After completing the pro-
gramme, both leaders and patients reported on the adher-
ence with regard to homework assignments (e.g. drawing
up weekly action plans).
Immediately after the programme, patients who had
attended at least three of the six sessions received a struc-
tured evaluation form to assess their opinion about the
CDSMP. They were asked to what extent they had bene-
fited from the programme (5-point scale; not benefited –
Table 2: Outcome variables of the effect evaluation
Variables No. of items Range* BM FU1 FU2 FU3
Primary outcome variables
General self-efficacy (GSES) [12] 16 16–80 QQ Q Q
Cardiac self-efficacy [16]
Control symptoms 8 0–32 QQ Q Q
Maintain function 5 0–20 QQ Q Q
Perceived control [17] 7 7–35 TI TI TI TI
Cognitive symptom management [20] 5 0–25 TI TI TI TI
Secondary outcome variables
Smoking behaviour 2 N/A TI TI TI TI
Drinking behaviour 2 N/A TI TI TI TI
BMI 2 N/A TI TI TI TI
Physical activity [20] 4 N/A TI TI TI TI
Self-care behaviour (EHFScBS) [21] 12 12–60 QQ Q Q
General quality of life (RAND-36) [22]
Physical functioning 10 0–100 QQ Q Q
Social functioning 2 0–100 QQ Q Q
Role limitations (physical problem) 4 0–100 QQ Q Q
Role limitations (emotional problem) 3 0–100 QQ Q Q
Mental health 5 0–100 QQ Q Q
Vitality 4 0–100 QQ Q Q
Pain 2 0–100 QQ Q Q
General health perception 5 0–100 QQ Q Q
Health change 1 0–100 QQ Q Q
Cardiac quality of life (KCCQ) [23]
Physical limitations 6 0–100 QQ Q Q
Symptoms 8 0–100 QQ Q Q
Self-efficacy 2 0–100 QQ Q Q
Social interference 4 0–100 QQ Q Q
Quality of life 3 0–100 QQ Q Q
Perceived autonomy 1 0–100 QQ Q Q
Symptoms of anxiety & depression [24, 25]
Anxiety (HADS-A) 70 –21 Q Q Q Q
Depression (HADS-D) 70 –21 Q Q Q Q
Health care utilisation 7 N/A TI TI TI TI
Covariates
Socio-demographic variables 9 N/A TI - - -
Co-morbidity [13, 28] 19 N/A TI - - -
Cognitive status (TICS) [29] 25 0–41 TI - - -
BM = baseline measurement; FU1 = immediate follow-up; FU2 = follow-up after 6 months; FU3 = follow-up after 12 months; Q = questionnaire; TI 
= telephone interview
N/A = not applicable
* Underlined scores indicate the most favourable scores.BMC Health Services Research 2006, 6:91 http://www.biomedcentral.com/1472-6963/6/91
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benefited very much), and which parts they did or did not
appreciate. In addition, patients were asked: (1) to give
report marks for the quality of the professional leader and
the peer leader, and the programme itself (10-point scale;
1 to 10), (2) whether they would recommend the CDSMP
to other CHF patients or to patients with other chronic
diseases (e.g. diabetes mellitus), and (3) whether the pro-
gramme had helped them improve specific health behav-
iours and coping strategies, compared with the situation
before they attended the programme. Finally, the patients
were asked to suggest improvements to the CDSMP.
The leaders' opinions about the programme were assessed
after each session (report mark on the session, strong and
weak points of the session) and after they had completed
the programme (report mark on their own skills as leader
and questions about the perceived benefits to the
patients). At the end of the intervention period (January
2006), all leaders were invited for a structured group inter-
view. During this meeting, the leaders evaluated the feasi-
bility of the protocol in more general terms and made
recommendations to improve the CDSMP.
Data collection
Data for the effect evaluation were collected at baseline
and the three follow-up assessments by means of self-
administered questionnaires and telephone interviews
(see table 2). The telephone interviews were conducted
independently by trained interviewers and started two
weeks after the questionnaires had been sent out. Patients
who announced their intention to stop during the study
were asked to complete at least the last follow-up assess-
ment (questionnaire and/or telephone interview).
Data for the process evaluation were collected from the
patients by means of self-administered questionnaires.
Recording forms and self-administered questionnaires
were used to gather data from the CDSMP leaders (see
table 3). In addition, bi-monthly structured meetings
were held to allow the leaders to discuss their experiences
with the various CDSMP classes.
Power calculation
The sample size calculation was based on figures derived
from Dutch research among newly diagnosed older CHF
patients [21] relating to one of the primary outcome vari-
ables in the present study, general self-efficacy expectan-
cies (GSES by Sherer and colleagues [20]). To detect a
mean difference of at least 4.0 points in general self-effi-
cacy expectancies between the intervention and control
groups (SD = 11.8; equivalent to an effect size of 0.34), at
least 137 patients in both the intervention and control
groups were required to achieve a power of 80% at an
alpha of 0.05 (one-sided). Assuming a drop-out rate of
30% during the trial, a total of 2× 180 patients have to be
included in the study.
Table 3: Outcome variables of the process evaluation
Process evaluation outcome variables BDP FU1 FU2
Programme performed according to protocol
Duration of each session RFl --
Deviations from the protocol RFl --
Attendance by the patients
Reasons for refusal before start of the programme TIp --
Number of sessions attended by each patient RFl --
Reasons for stopping during the programme TIp --
Adherence by patients
Overall adherence RFl --
Adherence regarding homework assignments - Qp/Ql -
Opinion about the programme
Extent of benefits from the programme - Qp Qp
Strong and weak points of the programme (sessions) RFl Qp/Ql -
General opinion about the quality of the leaders Qp/Ql -
General opinion about the programme RFl Qp/Ql-
Recommending the programme to other patients - Qp -
Programme contributions -Q p/Ql Qp
Recommendations for improvement - Qp/Ql -
BDP = before or during programme; FU1 = immediate follow-up; FU2 = follow-up at 12 months; RF = recording form (filled in after each session); 
Q = questionnaire; TI = telephone interview
Data collected from: l = leaders; p = patientsBMC Health Services Research 2006, 6:91 http://www.biomedcentral.com/1472-6963/6/91
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Analysis
Descriptive techniques will be used to characterise the
patients participating in the study. Data of the effect eval-
uation will be analysed according to the intention-to-treat
and per-protocol principles. Differences between the
intervention and control groups with regard to the pri-
mary and secondary outcome variables at the follow-up
assessments will be analysed with multivariate techniques
adjusting for possible differences in baseline scores and
background characteristics. Intervention group patients
will be included in the per-protocol analysis if they have
attended at least four of the six programme sessions.
Data of the process evaluation will be analysed for
patients and leaders by means of descriptive analysis.
Discussion
Progress of the study
Between July 2004 and November 2005, a total of 717 eli-
gible patients were selected for inclusion from six Heart
Failure and/or Cardiology Outpatient Clinics, 339 of
whom (47.3%) signed the informed consent form and
underwent the baseline assessment (see figure 2). The
remaining 378 patients refused or were unable to partici-
pate in the study for various reasons: for example, 84
Flow of the patients until randomisation Figure 2
Flow of the patients until randomisation.
Eligible patients screened 
from Outpatient Clinics 
N= 717 
Informed Consent  
N= 339 (47,3%) 
Refused participation (N= 378) 
x Physical problems (N= 84)  
x No interest (N= 74) 
x No time/opportunity (N= 74) 
x Psycho-social problems (N= 39) 
x Problems attending group programme (N= 22) 
x Cognitive problems (N= 12) 
x Reason unknown (N= 48) 
x Other reasons (N= 25) 
RANDOMISATION
(after completion
of baseline assessment) 
N= 318 
Intervention group 
N=  187 
Control group 
N= 131 
Not allocated (N= 21) 
x Incomplete baseline assessment (N= 20) 
(health problems, questions too personal…)  
x Died before allocation (N= 1) BMC Health Services Research 2006, 6:91 http://www.biomedcentral.com/1472-6963/6/91
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patients did not participate because of physical health
problems, 74 patients were not interested or felt no need
to participate, and another 74 patients had no time or
opportunity to participate (see figure 2). After completion
of the baseline assessment, 318 patients were included in
the trial; 187 patients were allocated to the intervention
group and 131 to the control group.
We had calculated that the study would require a sample
size of 2 × 180, including a 30% drop-out rate. A total of
187 patients were allocated to the intervention group,
which was according to plan. The number of patients allo-
cated to the control group (n = 131), however, was smaller
than planned. At present, follow-up data are being col-
lected. The exact drop-out rate and related consequences
for the power calculation will become clear after comple-
tion of the data collection in January 2007.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
GK developed the project and obtained funding together
with JvE and JvH. ES is the investigator and has worked
together with EvH in developing the materials for the
study, with input from the other authors. ES drafted the
manuscript, with input from the other authors. All
authors read and approved the final manuscript.
Acknowledgements
This research project was funded by the Netherlands Heart Foundation 
(2002B005) and the University Hospital Maastricht, the Netherlands (PF 
179). This study was conducted within the CAre and Public Health 
Research Institute (CAPHRI) of Maastricht University in the Netherlands, 
in cooperation with Lorig and colleagues from Stanford University, USA. 
We would like to thank N. Steverink, H.A. Elzen, and J.P. Slaets of the Uni-
versity Hospital Groningen (the Netherlands) for their willingness to share 
Dutch programme materials. Finally, we want to thank the University Hos-
pital Maastricht, Atrium Medical Centre Heerlen, VieCuri Medical Centre 
Venlo, Laurentius Hospital Roermond, Maasland Hospital Sittard, and Elk-
erliek Hospital Helmond for participating in the study.
References
1. Dickstein K, Jaarsma T: Heart failure management pro-
grammes: delivering the message.  Eur J Heart Fail 2005,
7:291-293.
2. Stewart S, MacIntyre K, Capewell S, McMurray JJ: Heart failure and
the aging population: an increasing burden in the 21st cen-
tury?  Heart 2003, 89:49-53.
3. Clark RA, McLennan S, Dawson A, Wilkinson D, Stewart S: Uncov-
ering a hidden epidemic: a study of the current burden of
heart failure in australia.  Heart Lung Circ 2004, 13:266-273.
4. van Jaarsveld CH, Sanderman R, Miedema I, Ranchor AV, Kempen GI:
Changes in health-related quality of life in older patients with
acute myocardial infarction or congestive heart failure: a
prospective study.  J Am Geriatr Soc 2001, 49:1052-1058.
5. Blue L, McMurray J: How much responsibility should heart fail-
ure nurses take?  Eur J Heart Fail 2005, 7:351-361.
6. DeWalt DA, Malone RM, Bryant ME, Kosnar MC, Corr KE, Rothman
RL, Sueta CA, Pignone MP: A heart failure self-management
program for patients of all literacy levels: a randomized, con-
trolled trial [ISRCTN11535170].  BMC Health Serv Res 2006,
6:30.
7. Jaarsma T, Halfens R, Huijer Abu-Saad H, Dracup K, Gorgels T, van
Ree J, Stappers J: Effects of education and support on self-care
and resource utilization in patients with heart failure.  Eur
Heart J 1999, 20:673-682.
8. Martensson J, Stromberg A, Dahlstrom U, Karlsson JE, Fridlund B:
Patients with heart failure in primary health care: effects of
a nurse-led intervention on health-related quality of life and
depression.  Eur J Heart Fail 2005, 7:393-403.
9. Sethares KA, Elliott K: The effect of a tailored message inter-
vention on heart failure readmission rates, quality of life, and
benefit and barrier beliefs in persons with heart failure.  Heart
Lung 2004, 33:249-260.
10. Schechter CB, Walker EA: Improving adherence to diabetes
self-management recommendations.  Diabetes Spectr 2002,
15:170-175.
11. Belardinelli R, Georgiou D, Cianci G, Purcaro A: Randomized, con-
trolled trial of long-term moderate exercise training in
chronic heart failure: effects on functional capacity, quality
of life, and clinical outcome.  Circulation 1999, 99:1173-1182.
12. Living with heart failure   [http://www.patienthealthinterna
tional.com/article/501796.aspx]
13. Health Library   [http://12.31.13.50/library/healthguide/en-us/ill
nessconditions/topic.asp?hwid=support/tp17534]
14. Lorig K, Holman H, Sobel D, Laurent D, Gonzalez V, Minor M: Living
a healthy life with chronic conditions: self-management of heart disease,
arthritis, diabetes, asthma, bronchitis, emphysema and others Boulder,
Colorado: Bull Publishing Company; 2000. 
15. Lorig KR, Ritter P, Stewart AL, Sobel DS, Brown BW Jr, Bandura A,
Gonzalez VM, Laurent DD, Holman HR: Chronic disease self-
management program: 2-year health status and health care
utilization outcomes.  Med Care 2001, 39:1217-1223.
16. Lorig KR, Sobel DS, Ritter PL, Laurent D, Hobbs M: Effect of a self-
management program on patients with chronic disease.  Eff
Clin Pract 2001, 4:256-262.
17. Lorig KR, Sobel DS, Stewart AL, Brown BW Jr, Bandura A, Ritter P,
Gonzalez VM, Laurent DD, Holman HR: Evidence suggesting that
a chronic disease self-management program can improve
health status while reducing hospitalization: a randomized
trial.  Med Care 1999, 37:5-14.
18. Lorig KR, Holman H: Self-management education: history, def-
inition, outcomes, and mechanisms.  Ann Behav Med 2003,
26:1-7.
19. Bandura A: Self-efficacy: the exercise of control New York: Freeman;
1997. 
20. Sherer M, Maddux JE, Mercandante B, Prentice-Dunn S, Jacobs B,
Rogers RW: The self-efficacy scale: construction and valida-
tion.  Psychol Rep 1982, 51:663-671.
21. Kempen GI, Sanderman R, Miedema I, Meyboom-de Jong B, Ormel J:
Functional decline after congestive heart failure and acute
myocardial infarction and the impact of psychological
attributes. A prospective study.  Qual Life Res 2000, 9:439-450.
22. Lorig K, Gonzalez V: The integration of theory with practice: a
12-year case study.  Health Educ Q 1992, 19:355-368.
23. Lorig KR, Ritter PL, Jacquez A: Outcomes of border health Span-
ish/English chronic disease self-management programs.  Dia-
betes Educ 2005, 31:401-409.
24. Sullivan MD, LaCroix AZ, Russo J, Katon WJ: Self-efficacy and self-
reported functional status in coronary heart disease: a six-
month prospective study.  Psychosom Med 1998, 60:473-478.
25. Arnold R: Quality of life in chronic obstructive pulmonary dis-
ease and chronic heart failure: disease-specific and generic
factors in adaptation to illness.  In PhD thesis University of Gron-
ingen, Department of Health Sciences; 2004. 
26. Arnold R, Ranchor AV, DeJongste MJ, Koeter GH, Ten Hacken NH,
Aalbers R, Sanderman R: The relationship between self-efficacy
and self-reported physical functioning in chronic obstructive
pulmonary disease and chronic heart failure.  Behav Med 2005,
31:107-115.
27. Pearlin LI, Schooler C: The structure of coping.  J Health Soc Behav
1978, 19:2-21.
28. Bosscher RJ, Smit JH, Kempen GI: Algemene competentiever-
wachtingen bij ouderen: Een onderzoek naar de psychome-
trische kenmerken van de Algemene CompetentieschaalPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Health Services Research 2006, 6:91 http://www.biomedcentral.com/1472-6963/6/91
Page 10 of 10
(page number not for citation purposes)
(ALCOS) [Global expectations of self-efficacy in the elderly:
An investigation of psychometric characteristics of the Gen-
eral Self-Efficacy Scale].  Ned Tijdschr Psychol 1997, 52:239-248.
29. Kempen GI: Psychometric properties of GLAS baseline measures: a pilot
study (in Dutch) Groningen, The Netherlands: Northern Centre for
Healthcare Research; 1992. 
30. Lorig K, Stewart A, Ritter P, Gonzalez V, Laurent D, Lynch J: Outcome
measures for health education and other health care interventions Thou-
sand Oaks, California: Sage Publications, Inc; 1996. 
31. Jaarsma T, Stromberg A, Martensson J, Dracup K: Development
and testing of the European Heart Failure Self-Care Behav-
iour Scale.  Eur J Heart Fail 2003, 5:363-370.
32. Hays RD, Sherbourne CD, Mazel RM: The RAND 36-Item Health
Survey 1.0.  Health Econ 1993, 2:217-227.
33. Green CP, Porter CB, Bresnahan DR, Spertus JA: Development
and evaluation of the Kansas City Cardiomyopathy Ques-
tionnaire: a new health status measure for heart failure.  J Am
Coll Cardiol 2000, 35:1245-1255.
34. Zigmond AS, Snaith RP: The hospital anxiety and depression
scale.  Acta Psychiatr Scand 1983, 67:361-370.
35. Bjelland I, Dahl AA, Haug TT, Neckelmann D: The validity of the
Hospital Anxiety and Depression Scale. An updated litera-
ture review.  J Psychosom Res 2002, 52:69-77.
36. Spinhoven P, Ormel J, Sloekers PP, Kempen GI, Speckens AE, Van
Hemert AM: A validation study of the Hospital Anxiety and
Depression Scale (HADS) in different groups of Dutch sub-
jects.  Psychol Med 1997, 27:363-370.
37. van der Zee KI, Sanderman R: Het meten van de algemene gezondheids-
toestand met de RAND-36, een handleiding Groningen: Noordelijk Cen-
trum voor Gezondheidsvraagstukken; 1993. 
38. Kempen GI, Ranchor AV, Ormel J, van Sonderen E, van Jaarsveld CH,
Sanderman R: Perceived control and long-term changes in dis-
ability in late middle-aged and older persons: An eight-year
follow-up study.  Psychol Health 2005, 20:193-206.
39. Kempen GI, Meier AJ, Brouwens SF, van Deursen J, Verhey FR: Tel-
efonisch Interview Cognitieve Status (TICS): psychome-
trische aspecten [Psychometric properties of the Dutch
version of the Telephone Interview Cognitive Status
(TICS)].  Tijdschr Gerontol Geriatr  in press.
40. Brandt J, Spencer M, Folstein M: The Telephone Interview for
Cognitive Status.  NNBN 1988, 1:111-117.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1472-6963/6/91/prepub